Dendreon Corp fka DNDNQ

[nerdseeksblonde]

that sounds more credible
anyway than the last suit. I have to confess to
ignoring some details here on what mgmt said and
the specific trading rules but clearly anything
that gets more disclosure is good for everyone
as long as legitimate competitive interests and IP
rights are maintained.

These are the kind of not-so-publicized things that, if
they exist regardin the clinical dat and are brough out, would extend the class period well prior to the AC meeting.

Whatever happened to the mono data once the tax+pro data came out? Did anyone
ever come up with a model they felt good about or see credible numbers? Instead of the fixation on a stupid accounting judgment, most investors would be concerned about the known attributes of the only near-term product...